Thrombosis is intricately linked with inflammation, which leads to multiple major clinical disorders including disseminated intravascular coagulation and acute ischemic events.
Introduction
Untoward thrombus formation is associated with multiple major clinical disorders and is a leading cause of death and disability worldwide (1) . Excessive platelet activation and aggregation at sites of disrupted vascular integrity typically induce thrombosis, which may result in acute vessel occlusion and ischemic events (1-2). Thrombus formation is inseparably linked with inflammation, and recent emphasis on the role of platelets as sentinel innate immune cells suggests that platelets provide a unique link between coagulation and immune reponses (3-6).
High-mobility group box 1 (HMGB1), a highly conserved, non-histone, architectural DNA-binding nuclear protein, acts as a damage associated molecular pattern molecule (DAMP) when released by dying cells or actively secreted by mononuclear and other cells, initiating inflammation (7-10). Although lacking a nucleus, platelets express HMGB1, and, following platelet activation, HMGB1 is both exported to the cell surface as well as released into the extracellular space (11-13). Serum/plasma levels of HMGB1 are upregulated in multiple inflammatory disease states associated with abnormal coagulation including myocardial infarction (14) (15) , stroke (14) , sepsis (16) , disseminated intravascular coagulation (DIC) (17) , trauma (18-19), and hemorrhagic shock (20). Moreover, diverse biological functions of extracellular HMGB1 bear striking similarities to those assigned to activated platelets, including microvascular endothelial inflammation (8), leukocyte recruitment (19), and microvascular thrombosis (21), indicating that platelet-derived HMGB1 may link inflammation and thrombosis.
HMGB1 signals through agonist receptors such as the receptor for advanced glycation end products (RAGE) as well as other pattern recognition receptors including TLR2, TLR4, and TLR9 (22-23). Platelets express the agonist receptors (24-25), suggesting a potential role for HMGB1 signaling through these molecules. Particular importance is ascribed to
Results

Platelet-derived HMGB1 mediates platelet aggregation and thrombosis
We utilized a cre/loxp system to create transgenic mice with ablation of HMGB1 in platelets (PF4-Cre; HMGB1 loxp/loxp , termed HMGB1 PF4 mice) and investigated the role of platelet-derived HMGB1 in hemostasis. The mice were comparable with Flox control mice (data not shown).
We next investigated the role of platelet-derived HMGB1 in an in vivo model of thrombosis. In ferric chloride (FeCl3)-induced thrombosis, reduction of blood flow in the mesenteric artery, indicating thrombus formation, was substantially prolonged in HMGB1 PF4 mice as compared with the HMGB1 Flox control ( Figure 1D ). The time from injury to formation of stable occlusive thrombus (time to occlusion) was significantly elevated in mice with the platelet-specific HMGB1 knockout as compared with control mice (18.7 ± 1.0 min vs. 13.25 ± 3.3 min, p<0.019) ( Figure 1E , F). Isolated FeCl3-induced clots were further subjected to immunofluorescence staining ( Figure 1G ) and Western blot analysis ( Figure 1H ).
CD41 positive platelet aggregates in thrombi derived from Flox control mice were substantially decreased in HMGB1 PF4 mice ( Figure 1G ). HMGB1, which was adjacent to platelet aggregates in Flox control mice, was not detected in the platelet-specific knockout animals. Western blot analysis revealed a substantial loss of HMGB1 abundance in the clots taken from HMGB1 PF4 mice, suggesting that platelets are the major source of HMGB1 in thrombus ( Figure 1H ).
We and others have previously shown that platelets store and, upon activation, express HMGB1 on their surface (12) and release significant amounts into the extracellular space (13). To test HMGB1 expression during thrombus formation, we perfused blood, which was previously stained with a labelled anti-HMGB1 antibody, through a flow chamber over a collagen coated surface with high shear rates (1700 s -1 ) and performed live imaging of the forming thrombi in vitro. Significant HMGB1 expression was detected during a 100 second investigation period (Supplemental Figure 2) .
Platelet-derived HMGB1 promotes platelet aggregation and small vessel thrombosis in the lung and liver during trauma and hemorrhagic shock
Having detected platelet-derived HMGB1 as a critical factor for platelet aggregation and platelet-dependent thrombus formation, we investigated platelet-HMGB1 and its effects during trauma and hemorrhagic shock. In trauma patients, expression of HMGB1 on circulating platelets (CD42b+HMGB1+) was significantly elevated on the same day of the event (day 1) (p<0.05), as well as one (day 2) (p<0.005) and two days (day 3) (p<0.002)
following the event as compared with healthy subjects and evaluated by flow cytometry (Figure 2A ). Significant (p<0.004) differences within the four subgroups were detected.
In an experimental trauma/hemorrhagic shock model, consisting of soft tissue injury, bone pseudofracture, hemorrhage, and liver crush, systemic aggregation of circulating platelets was significantly (p<0.001) increased in HMGB1 Flox control mice 30 min after induction of trauma ( Figure 2B ). This "aggregation peak" was not detected in mice with the 
HMGB1-dependent thrombosis and platelet aggregation is mediated via TLR4/MyD88
To further study the in vivo effect of HMGB1 on thrombus formation, we used the FeCl3 model with tail vein injection of either recombinant HMGB1 (rHMGB1) (1 µg/g body weight) or PBS control prior to induction of thrombosis ( Figure 3A) . Injection of rHMGB1 resulted in a marked reduction of blood flow in the damaged mesenteric artery and a significantly decreased time to occlusion as compared with the PBS control, confirming an HMGB1-induced prothrombotic effect. To test the in vivo effect of HMGB1 on platelet aggregation, we performed immunofluorescence staining of platelets (CD41) in liver and lung tissue sections after injection of rHMGB1 or PBS control into mice ( Figure 3B ). Significantly increased platelet sequestration in lung (p<0.008) and liver (p<0.05) of the rHMGB1-injected animals was observed.
Next, we analyzed the molecular mechanism underlying HMGB1-mediated thrombosis and platelet aggregation. For this purpose we performed the FeCl3 model with injection of rHMGB1 or PBS prior to induction of thrombosis in transgenic mice with ablation of TLR4 in platelets (PF4-Cre; TLR4 loxp/loxp , termed TLR4 PF4 mice) ( Figure 3C ). As compared with PBS injections, rHMGB1 treatment of TLR4 Flox control mice resulted in a significantly decreased time to occlusion, confirming the prothrombotic effect of HMGB1.
However, injection of rHMGB1 in TLR4 PF4 mice failed to decrease the time to occlusion.
Thus, the HMGB1-induced prothrombotic effect was mediated via platelet-TLR4.
To further study the underlying pathway, we performed flow chamber experiments with WT mouse blood, which was either untreated or preincubated with rHMGB1 for 30 min ( Figure 3D ). As compared with untreated blood, treatment with rHMGB1 resulted in a significant (p<0.003) increase in thrombus formation, confirming prothrombotic activity of HMGB1. However, in mice lacking TLR4 (TLR4 -/-) or MyD88 (MyD88 -/-), the HMGB1-induced prothrombotic effect was lost (TLR4 -/-: 30.9 ± 7.7 % inhibition, p<0.007; MyD88 -/-:
40.7 ± 8.2 % inhibition, p<0.004). We also studied the influence of HMGB1 on platelet aggregation and the contribution of TLR4 and MyD88 ( Figure 3E ). Next, we studied the potential contribution of cGKI to HMGB1-mediated platelet aggregation and thrombus formation using cGKI knockout platelets (cGKI -/-). Flow chamber experiments revealed that incubation of cGKI-deficient blood with rHMGB1 was followed by a significantly reduced prothrombotic effect as compared with treatments of control mice (26.4 ± 14.2 % inhibition, p<0.003) ( Figure 4D ). Moreover, platelet aggregation induced by adding rHMGB1 to platelets from control mice (data not shown) was almost completely abolished in cGKI -/-platelets ( Figure 4E ). To confirm this observation in vivo, we injected mice with rHMGB1 in the presence or absence of DT-2, a cGKI inhibitor (36), prior to induction of thrombosis using a FeCl3 model ( Figure 4F , G). HMGB1-induced reduction of blood flow in the damaged mesenteric artery indicating clot formation was significantly reversed in the presence of DT-2 ( Figure 4G ).
HMGB1 induces MyD88-dependent recruitment of GC to the platelet plasma membrane followed by MyD88/GC complex formation and increased cGMP production in platelets
Having identified a critical role for the HMGB1/TLR-4/MyD88 pathway-mediated cGKI activation in platelet aggregation and thrombus formation, we next investigated whether HMGB1-induced cGKI activation in platelets is dependent on the second messenger cGMP.
We determined the presence of GC, a critical enzyme of the nitric oxide signaling pathway that produces cGMP, and studied possible interaction of GC with MyD88 in platelets. Figure   5A shows representative immunofluorescence confocal laser-scanning microscopy images of Figure 5D ). Furthermore, DEA/NO did not promote MyD88/GC complex formation, whereas LPS did ( Figure 5C ). The reciprocal immunoprecipitation was also performed with comparable results ( Figure 5E , F). Thus, we could detect HMGB1-induced complex formation of MyD88 and GC in platelets.
To determine if this HMGB1-induced complex formation is followed by GC activation, murine platelets were incubated with graded doses of rHMGB1, and intracellular levels of cGMP were monitored by an enzyme-linked immunoassay. HMGB1 significantly increased cGMP levels in WT platelets in a dose-dependent manner as compared with untreated controls ( Figure 5G ). However, HMGB1-driven upregulation of cGMP did not occur in MyD88 -/-platelets, indicating a MyD88-dependent phenomenon. LPS-induced cGMP production was also reversed in MyD88 -/-platelets, whereas DEA/NO increased cGMP levels in a MyD88-independent fashion. A schematic overview of the identified mechanism underlying HMGB1-driven platelet aggregation and thrombus formation is presented in Figure 6 .
Discussion
HMGB1 is an endogenous DAMP (37) critical to the pathogenesis of disorders associated with abnormal coagulation such as trauma, hemorrhagic shock, and sepsis (16, (18) (19) (20) (21) . A procoagulant role of HMGB1 in a thrombin-induced DIC rat model has been reported (21), and in patients with DIC, blood levels of HMGB1 correlated with platelet activation markers (38) and sepsis-related organ failure (17) . Platelets store and, upon activation, express on the cell surface and release HMGB1 (11-13). The role of platelet-derived HMGB1 in platelet function and thrombus formation, however, previously remained unexplored.
Unexpectedly, we now identify platelet-specific HMGB1 as a novel mediator for thrombosis.
Platelet aggregation, intravascular thrombus formation and organ injury induced by trauma and hemorrhagic shock were critically regulated by platelet-derived HMGB1. HMGB1
exerted the effect via TLR4 and MyD88-dependent recruitment of GC towards the platelet plasma membrane, followed by formation of a downstream complex between MyD88 and GC, activation of GC, and cGMP-dependent cGKI activation in platelets.
A diverse collection of cytokines, chemokines and DAMPs such as cyclophilin A (39-40), mitochondria (41), macrophage migration inhibitory factor (42), and HMGB1 (13) have been detected in platelets, and their release by platelets potentially links thrombosis with inflammation. Moreover, excessive platelet activation, e.g. during acute coronary or other thrombotic events, may result in formation of circulating monocyte-platelet aggregates, which constitutes a critical step in linking thrombosis with inflammation (43) (44) . In this study, the presence of the DAMP HMGB1 in platelets was critical for thrombus formation and organ injury. Thus, our findings highlight a novel regulatory role of platelet-derived HMGB1.
To further study the pathophysiological relevance of platelet-HMGB1, we utilized a murine model of trauma and hemorrhagic shock. Trauma is associated with coagulation abnormalities, with significant risks of both micro-and macrovascular thrombosis (28, [31] [32] 45 (50) and hepatic (51) injury after induction of ischemia-reperfusion damage have been reported, as well. The present study suggests targeting platelet-derived HMGB1 as a new and promising strategy to limit platelet-dependent thrombosis in organs at risk.
HMGB1 promoted platelet aggregation and thrombus formation via platelet TLR4, indicating yet another role for platelets as sentinel innate immune regulators. Downstream of TLR4, HMGB1 initiated recruitment of GC towards the platelet plasma membrane in a MyD88-dependent fashion, followed by formation of a MyD88/GC complex and MyD88-dependent elevation of intracellular cGMP levels in platelets, possibly as a consequence of the MyD88/GC complex, although this remains unproven. Further studies are required to decipher the specific mechanism that mediates HMGB1-driven MyD88/GC complex formation in platelets and its contribution to linking the TLR4/MyD88 pathway with the cGMP/cGKI pathway and thereby inflammation with hemostasis and thrombosis. Platelet aggregation and thrombus formation mediated by platelet-derived HMGB1 might predominantly occur via its release by activated platelets into extracellular space followed by autocrine and/or paracrine mechanisms, expression on the surface of activated platelets, which we observed in trauma patients in this study, or intracellular mechanisms. In each case, MyD88/GC complex formation in platelets may be critical for mediating the prothrombotic effect of platelet-derived HMGB1, which is currently under investigation. Designing specific inhibitors that interfere with this novel molecular link could be of particular relevance for patients sustaining trauma and other diseases, where inflammation and microvascular thrombosis go hand in hand (31) (32) .
Controversy exists in the literature regarding the role of cGMP/cGKI pathway in platelet activation and aggregation, as inhibitory (52-53) as well as stimulatory (29, 54) effects of cGMP-dependent cGKI activation in platelets have been previously shown. A biphasic cGMP response, consisting of an early stimulatory response promoting platelet activation and aggregation followed by a delayed inhibitory response, which is dependent on duration and concentration of cGMP levels in platelets, has been proposed as a possible explanation for this (29) . Moreover, platelet GC plays an important stimulatory role in hemostasis and thrombosis in vivo, which has been shown in mice with a platelet specific soluble GC knockout (55) . In our study, HMGB1 upregulated cGMP levels in platelets and induced activation of platelet cGKI, as measured by phosphorylation of VASP, which was followed by substantially enhanced platelet aggregation and thrombus formation. Thus, our findings confirm a stimulatory effect on platelets upon GC/cGKI activation, which may be critical for inflammation-induced abnormal platelet activation and aggregation.
platelet-dependent thrombus formation and organ injury induced by trauma and hemorrhagic shock. Interfering with HMGB1-driven TLR4/MyD88/GC/cGMP/cGKI signaling in platelets may reduce thrombotic events followed by imminent organ dysfunction as well as improve efficacy of current anti-platelet treatment strategies. Thus, our findings offer new therapeutic options for patients suffering from trauma and potentially in other inflammatory diseases associated with abnormal coagulation.
Methods
Animals
Platelet-specific HMGB1 knockout mice were generated by crossing floxed HMGB1
(HMGB1 loxp/loxp , termed HMGB1 Flox mice) (33) with platelet factor (PF4)-Cre transgenic mice (34) (Jackson Laboratories, Bar Harbor, ME). As both mouse strains were on C57BL/6 background, all progeny used in our study were generated with C57BL/6 mice with pure genetic backgrounds. PF4-Cre; HMGB1 loxp/loxp (termed HMGB1 PF4 mice) offspring were confirmed using standard genomic PCR genotyping techniques. Deletion of HMGB1 was confirmed by immunofluorescence staining for HMGB1 on isolated platelets using an anti-HMGB1 polyclonal antibody (2 µg/ml; rabbit IgG; Sigma-Aldrich, St. Louis, MO)
( Supplementary Fig. 1a ) and Western Blot of isolated platelets with anti-HMGB1 polyclonal antibody (1 µg/ml; rabbit IgG; Abcam, Cambridge, UK) ( Supplementary Fig. S1b ).
Circulating platelet counts were assessed using an automated cell counter (Beckman Coulter, Brea, CA). C57BL/6 mice were purchased from Jackson Laboratories. Global RAGE with PF4-Cre transgenic mice as described (28). Smooth muscle-specific cGKIβ rescue mice, i.e. transgenic mice with global cGKI knockout and selective re-expression of cGKIβ in smooth muscle cells (termed cGKI KO), were generated as previously described (60) .
Platelets from these mice are cGKI-deficient (cGKI -/-) and were used in this study. Smooth muscle-specific cGKIβ rescue mice and litter-matched control (Ctr) animals that express cGKI in platelets were bred, genotyped and housed at University of Tübingen, Germany. We used these rescue mice to study cGKI, since conventional global cGKI knockout mice have a decreased life span (50% die before 5 to 6 weeks of age), disturbed platelet activation and other abnormal cell functions (61).
Bleeding time
Mice were anesthetized and a 3-mm segment of the tail tip was removed with a scalpel. Tails were submerged in PBS and bleeding was monitored as previously described (62) . Bleeding time was quantified in seconds to time from initiation to cessation of blood flow.
Isolation of human and murine platelets
Human and murine platelets were isolated as previously described (13, 63). Venous blood from healthy volunteers was collected in acid-citrate-dextrose (ACD)-buffer and centrifuged at 430 x g for 20 min. Platelet-rich plasma (PRP) was added to Tyrodes-HEPES buffer (HEPES, 2.5 mmol/l; NaCl, 150 mmol/l; KCl, 1 mmol/l; NaHCO 3 , 2.5 mmol/l; NaH 2 PO 4 , 0.36 mmol/l; glucose, 5.5 mmol/l; BSA, 1 mg/ml; pH 6.5) and cetrifuged at 900 x g for 10 min. The supernatant was discarded and the platelet pellet was suspended in Tyrodes-HEPES buffer (pH 7.4; supplemented with CaCl 2 , 1 mmol/l; MgCl 2 , 1 mmol/l). For the preparation of murine platelets, mice were anesthetized with isoflurane and blood was drawn from the retroorbital plexus into anticoagulated tubes. PRP was obtained by centrifugation at 260 x g for 5 min followed by another centrifugation step at 640 x g for 5 min to pellet the platelets.
Platelet aggregometry
Platelet aggregation was assessed using either impedance aggregometry (whole blood) or light transmission (isolated platelets) as indicated using a ChronoLog aggregometer (Model 700, Havertown, PA). Aggregation of isolated platelets was performed at a concentration of 2 x 10 8 platelets/µl in Tyrodes-HEPES buffer (pH 7.4). After adjusting the measurement according to the manufacturer's protocol, platelets were activated with either collagen (2 µg/ml; ChronoLog) or CRP (1 µg/ml; from Richard Farndale, University of Cambridge, Cambridge, UK), and platelet aggregation was measured in the presence or absence of 200 ng/ml recombinant HMGB1 (rHMGB1; R&D Sytems, Minneapolis, MN) for 10 min at 37°C
with a stir speed of 1200 rpm. Analysis was performed using the aggrolink-8 software (ChronoLog).
Flow chamber
Heparinized whole murine (C57BL/6 mice, ) for 5 minutes as described previously (63) . After perfusion the chamber was rinsed for 5 min by perfusion with Tyrodes-HEPES buffer and pictures were taken from 4-5 different microscopic areas (using 20x optical objectives). Analysis of thrombus area for each picture was performed with AxioVision software (Carl Zeiss, Jena, Germany) and the mean percentage values were determined for each experimental run. In certain experiments, blood was preincubated with 400 ng/ml rHMGB1 for 30 min at room temperature.
FeCl3 thrombosis model
FeCl3-induced thrombosis was performed on the mesenteric artery as previously described (42). Briefly, mice were anesthetized with intraperitoneal pentobarbital sodium (50 mg/kg body weight; Oak Pharmaceuticals, Lake Forest, IL). After a midline abdominal incision, the mesentery was exteriorized and the mesenteric artery was injured by topical application of a Whatman filter paper soaked with 10% FeCl3 (Sigma-Aldrich) for 30 s. Core 
Clot analysis
Following FeCl3-induced thrombosis, the excised intravascular clot was suspended in lysis buffer (Cell Signaling, Danvers, MA), dissociated by sonication and centrifuged at 7,000
x g for 10 min. The supernatant was then concentrated 10-fold with Amicon Ultra Centrifugal Filter Units (10 kDa; Merck Millipore, Tokyo, Japan), lysed with lysis buffer and subjected to
Western blot analysis using anti-HMGB1 polyclonal antibody (2 µg/ml; rabbit IgG; SigmaAldrich) and anti-Actin polyclonal antibody (1:1000; rabbit IgG; Abcam) as internal loading control.
For immunofluorescence staining, the clot was fixed in 4% paraformaldehyde after isolation and snap-frozen in liquid nitrogen prior to tissue sectioning and staining with antifibrinogen polyclonal antibody (5 µg/ml, rabbit IgG; Abcam), anti-HMGB1 polyclonal antibody (2 µg/ml, rabbit IgG; Sigma-Aldrich), and anti-CD41 monoclonal antibody (2 µg/ml, rat IgG1κ; BD Biosciences, San Jose, CA). Anti-rabbit (Cy3, presented as red), anti-rat Bone matrix preparation for pseudofracture Donor bones (tibia and femur) were removed from an age-and weight-matched syngenic donor, crushed using a mortar and pestle and resuspended in PBS as described (64) .
Polytrauma and hemorrhagic shock
Mice were anesthetized with intraperitoneal pentobarbital sodium ( 
Measurement of serum ALT and AST levels
To assess hepatic function and cellular injury following trauma/hemorrhagic shock, plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using the Dri-Chem 7000 Chemistry Analyzer (Heska, Loveland, CO).
Histopathology
Paraformaldehyde-fixed lung and liver samples derived from HMGB1 PF4 and HMGB1 Flox mice during experimental trauma/hemorrhagic shock were processed in a Shandon
Excelsior ES tissue processor (Thermo Scientific, Waltham, MA) with alcohol dehydration and xylene infiltration. Standard hematoxylin-eosin (HE) staining was performed to detect injured areas and intravascular thrombosis.
Detection of platelets in liver and lung with immunofluorescence staining
Immunofluorescence stainings of paraffin-embedded tissue sections of lung and liver were carried out with HMGB1 PF4 and HMGB1 Flox mice during experimental trauma/hemorrhagic shock as well as C57BL/6 mice that received tail vein injections of either rHMGB1 (1 µg/g body weight) or PBS control. Staining was performed using anti-F-actin monoclonal antibody (2 µg/ml, mouse IgM; Abcam) and anti-CD41 polyclonal antibody (2 µg/ml, rabbit IgG; Abcam). Samples were washed using PBS + 0.5% BSA followed by incubation in the appropriate Cy3 and Cy5 secondary antibodies (both 1:200; Jackson Laboratories). Samples were then thoroughly washed before incubation with nuclear stain (DAPI). Positively stained cells in six random fields were imaged with Olympus Fluoview 1000 microscopy (Olympus, Melville, NY). Quantification was performed utilizing a ratio of CD41 positivity to total actin.
Flow cytometric evaluation of HMGB1 expression on platelets
Blood samples from trauma patients and healthy volunteers were obtained from the 
Human sample collection
Inclusion and exclusion criteria for trauma patients are as follows.
Inclusion: Blunt traumatic injury; intact cervical spinal cord; patient arrival ≤ 6 hours of injury; admission to intensive care unit (ICU) from the emergency department (ED) and at least one of the following:
Lactate ≥ 2.5 or ; base deficit ≥ -3 or; hypotension < 90 mm hg Pre-hospital or Trauma Bay or; receiving blood in Trauma Bay or; requirement for rapid transport to OR with trauma, prior to CT.
Exclusion: Age <18; anticipated survival < 24 hrs; anticipated survival < 28 days due to pre-existing condition; isolated Traumatic Brain injury (Glascow Coma Score<8 after ICU admission) AND brain CT abnormality within 12 hr of injury; inability to obtain consent from the subject or legally authorized representative; pre-existing irnmunosuppression; transplant recipient; chronic high doses of steroids (>20 mg prednisone equivalents/day); admission to the ICU primary for substance withdrawal; known HIV positive status and CD4 count < 200 cells/mm 3 ; inability to obtain 1st blood sample within 6 hours of injury.
Western Blot analysis of P-VASP
Isolated murine platelets (3 x 10 8 /ml) were kept untreated or incubated with graded doses of rHMGB1 (20-400 ng/ml) or LPS (5 µg/ml; Sigma-Aldrich) for 15 min or the cGMP 
Immunofluorescence staining of intracellular MyD88 and GC in platelets
Human or murine platelets were isolated as described above, and untreated platelets 
Co-immunoprecipitation studies
Isolated murine platelets (10 9 /ml) were kept untreated or incubated with rHMGB1
(20,100 ng/ml) or LPS (5 µg/ml) for 15 min or DEA/NO (1 µM) for 5 min at room temperature. The preparations were then centrifuged at 640 x g for 5 min and the pellets were 
cGMP levels in platelets
Isolated platelets from MyD88 -/-and WT mice were kept untreated or incubated with DEA/NO (1 µM), rHMGB1 (20,100 ng/ml) or LPS (5 µg/ml) for 3 min. cGMP concentrations were determined using a cGMP enzyme-linked immunoassay kit (cGMP Direct Biotrak EIA; GE Healthcare) according to the manufacturer`s instructions.
Statistics
All data are presented as mean ± S.D. for N ≥3 unless stated otherwise. Statistical significance was determined with the Student's t test or one-way ANOVA using Graph Pad
Prism software (GraphPad, San Diego, CA, USA).
Study approval
Animal handling and care complied with published regulations by the US National . Schematic overview of the molecular mechanism underlying HMGB1-driven platelet aggregation and thrombosis. HMGB1 mediates platelet aggregation and thrombus formation via TLR4 and MyD88-dependent recruitment of GC towards the platelet plasma membrane, followed by MyD88/GC complex formation, GC activation, and cGMP-dependent activation of cGKI in platelets, which is followed by phosphorylation of VASP.
